Pioneering the Future of Antifungal Drugs
Biosergen is a biotech company focused on developing innovative antifungal drugs. With a strong emphasis on safety and potency, our lead product, BSG005, has shown promising results in treating invasive fungal infections in immunocompromised patients. Our mission is to provide effective treatments for those at risk, including individuals with AIDS, cancer, and transplant recipients.
Revolutionizing Antifungal Drug Development for a Healthier Future
Biosergen is a biotech company dedicated to revolutionizing antifungal drug development. With our lead product, BSG005, we aim to combat multidrug resistance and improve patient outcomes. Through innovation and collaboration, we are working towards creating novel treatments that address the global health threat posed by invasive fungal infections. Join us in our mission to advance antifungal drug development and make a positive impact on the lives of immunocompromised patients worldwide. Sign up to our press releases to learn more about our
groundbreaking work.
Advancing Antifungal Drug Development
We aim to revolutionize the field of antifungal drug development by creating novel treatments that combat multidrug resistance and improve patient outcomes.
Innovation and Collaboration
We believe in the power of collaboration and actively seek partnerships with leading researchers and institutions to accelerate the discovery and development of new antifungal drugs.
Improving Global Health
By addressing the growing threat of multidrug resistance, we strive to improve the lives of immunocompromised patients worldwide.
Biosergen: Who we are
Biosergen AB is a biotech company focused on developing innovative antifungal drugs. Our lead product, BSG005, has been developed in Trondheim and other global labs, demonstrating superior safety and potency compared to current treatments. We are dedicated to addressing the urgent need for effective treatments for invasive fungal infections in immunocompromised patients, including those with AIDS, cancer, and transplant recipients.
Executive Management
Biosergen has a very experienced management team. The experience extends from early stage to life cycle management, it covers a company span from start ups to large pharmaceutical companies. In addition to listed companies as well as non-listed companies.
Board of Directors
Biosergen´s board has vast experience in biotech industry spanning from development to commercialization and the financial aspects of pharmaceutical industry.
Governance
The company is has been listed at Nasdaq First North Growth Market, Stockholm since June 24, 2021.
Carnegie Investment Bank AB (publ)
+46 (0)73 856 42 65
certifiedadviser@carnegie.se
PricewaterhouseCoopers AB
Torsgatan 21
113 97 Stockholm
PricewaterhouseCoopers AB is represented by Johan Engstam, State Authorised Public Accountant,
Innovative Antifungal
Drugs by Biosergen
Discover our cutting-edge research on antifungal
drugs and their impact on patient care.
